Statin Effects to Reduce Hepatosteatosis as Measured by Computed Tomography in Patients With Human Immunodeficiency Virus

View/ Open
Author
Kim, Elli A.
Hallett, Travis R.
Park, Jakob
Published Version
https://doi.org/10.1093/ofid/ofw062Metadata
Show full item recordCitation
Lo, Janet, Michael T. Lu, Elli A. Kim, Eric Nou, Travis R. Hallett, Jakob Park, Udo Hoffmann, and Steven K. Grinspoon. 2016. “Statin Effects to Reduce Hepatosteatosis as Measured by Computed Tomography in Patients With Human Immunodeficiency Virus.” Open Forum Infectious Diseases 3 (2): ofw062. doi:10.1093/ofid/ofw062. http://dx.doi.org/10.1093/ofid/ofw062.Abstract
Hepatosteatosis is highly prevalent among patients living with human immunodeficiency virus. In a 1-year, randomized, double-blind trial of atorvastatin or placebo, atorvastatin increased liver/spleen ratio among patients with nonalcoholic fatty liver disease, indicating a reduction in hepatosteatosis. This reduction in hepatosteatosis is associated with reduction in low-density lipoprotein cholesterol with statin therapy.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4943550/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:27822361
Collections
- HMS Scholarly Articles [17734]
- SPH Scholarly Articles [6392]
Contact administrator regarding this item (to report mistakes or request changes)